Market Cap | 38.42B | P/E | 26.84 | EPS this Y | 7.00% | Ern Qtrly Grth | 8.70% |
Income | 1.08B | Forward P/E | - | EPS next Y | 10.90% | 50D Avg Chg | - |
Sales | 11.24B | PEG | - | EPS past 5Y | - | 200D Avg Chg | 5.00% |
Dividend | N/A | Price/Book | 2.34 | EPS next 5Y | - | 52W High Chg | -8.00% |
Recommedations | 1.50 | Quick Ratio | - | Shares Outstanding | 4.57B | 52W Low Chg | 49.00% |
Insider Own | 4.34% | ROA | - | Shares Float | 6.73B | Beta | - |
Inst Own | 8.78% | ROE | - | Shares Shorted/Prior | 23.97M/20.81M | Price | 8.32 |
Gross Margin | 61.94% | Profit Margin | 9.64% | Avg. Volume | 3,505,880 | Target Price | 9.72 |
Oper. Margin | 22.44% | Earnings Date | - | Volume | 2,987,466 | Change | -2.69% |
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Argus Research | Buy | Mar 26, 24 |
Morgan Stanley | Overweight | Nov 1, 23 |
Argus Research | Buy | Apr 6, 23 |
Argus Research | Hold | Sep 28, 22 |
Deutsche Bank | Hold | Jul 29, 22 |